Table 1. Patient baseline characteristics.
| complete collective n = 332 |
native aortic valve n = 293 |
TAVR n = 21 |
P–value | SAVR n = 18 |
|
|---|---|---|---|---|---|
| Age | 76.9 (±8.9) (332/332) | 76.7 (±8.9) (293/293) | 79.2 (±10.2) (21/21) | 0.05 | 76.6 (±6.3) (18/18) |
| Male gender | 57.2% (190/332) |
56.0% (164/293) | 66.7% (14/21) | 0.34 | 66.7% (12/18) |
| Coronary heart disease | 73.2% (243/332) | 71.0% (208/293) | 95.2% (20/21) | 0.02 | 83.3% (15/18) |
| Atrial fibrillation | 65.7% 218/332 | 67.6% (198/293) | 57.1% (12/21) | 0.33 | 44.4% 8/18 |
| Hypertension | 70.5% (234/332) | 70.0% (205/293) | 85.7% (18/21) | 0.12 | 61.1% (11/18) |
| Smoker | 17.2% 57/332 | 16.7% (49/293) | 23.8% (5/21) | 0.41 | 16.7% (3/18) |
| Hyperlipoproteinemia | 45.5% (151/332) | 44.0% (129/293) | 66.7% (14/21) | 0.04 | 44.4% (8/18) |
| Diabetes | 28.6% (95/332) | 28.3% (83/293) | 42.9% 9/21 | 0.16 | 16.7% (3/18) |
| NYHA-class | 3.2 (2 to 4) (325/332) | 3.2 (2 to 4) (286/293) | 3.4 (2 to 4) (21/21) | 0.11 | 3.1 (2 to 4) (18/18) |
| *Renal insufficiency | 47.9% (159/332) | 46.8% (137/293) | 71.4% (15/21) | 0.03 | 38.9% (7/18) |
| *Pulmonary hypertension | 65.2% (214/328) | 64.4% (186/289) | 76.2% (16/21) | 0.27 | 66.7% (12/18) |
| Euroscore II | 10.8 ± 10.3 (328/332) | 10.5 ± 10.4) (289/293) | 11.9 ± 6.4 (21/21) | 0.02 | 15.7 ± 11.4 (18/18) |
| LVEDD | 54.0 ± 10.0 (292/332) | 54.4 ± 9.9 (257/293) | 53.6 ± 9.2 (19/21) | 1.0 | 50.5 ± 12.2 (16/18) |
| LV Function | |||||
| ≤35% | 48.3% (160/331) | 49.7% (145/292) | 33.3% 7/21 | 0.15 | 44.4% (8/18) |
| 36–50% | 26.0% (86/331) | 22.9% 67/292 | 52.4% (11/21) | 0.003 | 44.4% (8/18) |
| >50% | 25.7% (85/331) | 27.4% (80/292) | 14.3% (3/21) | 0.19 | 11.1% (2/18) |
| Etiology of MR | |||||
| Functional | 51.7% (169/327) | 52.4% (151/288) | 42.9% 9/21 | 0.69 | 50% (9/18) |
| Degenerative | 48.3% 158/327 | 47.6% 137/288 | 57.1% 12/21 | 0.69 | 50% (9/18) |
| Betablockers | 87.6% 282/322 | 89.1% 253/284 | 71.4% (15/21) | 0.02 | 82.4% (14/17) |
| Aldosteronantagonist | 51.3% (164/320) | 53.5% (152/282) | 38.1% (8/21) | 0.16 | 23.5% (4/17) |
| ACE inhibitors/sartans | 83.8% (268/320) | 84.8% (239/282) | 66.7% (14/21) | 0.03 | 88.2% (15/17) |
| Diuretics | 88.5% (284/321) | 88.7% (251/283) | 85.7% (18/21) | 0.68 | 88.2% (15/17) |
| Digitalis | 10.3% 33/320 | 11.7% (33/282) | 0.0% (0/21) | 0.10 | 0.0% (0/17) |
| Calcium antagonists | 18.8% (60/319) | 18.1% (51/281) | 28.6% (6/21) | 0.24 | 17.6% (3/17) |
| Anticoagulation | 68.7% (222/323) | 70.2% (200/285) | 52.4% (11/21) | 0.09 | 64.7% (11/17) |
| General anesthesia | 25.9% (86/332) | 26.3% (77/293) | 33.3% (7/21) | 0.48 | 11.1% (2/18) |
| Deep sedation | 74.1% (246/332) | 73.7% (216/293) | 66.6% (14/21) | 0.48 | 88.9% 16/18 |
| No. of implanted clips | |||||
| 0 (failure) | 1.8% (6/332) | 1.4% (4/293) | 4.8% (1/21) | 0.23 | 5.6% (1/18) |
| 1 | 49.7% 165/332 | 48.1% (141/293) | 61.9% (13/21) | 0.23 | 61.1% (11/18) |
| 2 | 40.1% (133/332) | 41.3% (121/293) | 33.3% (7/21) | 0.47 | 27.8% (5/18) |
| 3 | 7.8% (26/332) | 8.5% 25/293 | 0.0% (0/21) | 0.16 | 5.6% (1/18) |
| 4 | 0.3% (1/332) |
0.3% (1/293) |
0.0% (0/21) |
0.79 | 0.0% (0/18) |
| 5 | 0.3% (1/332) |
0.3% (1/293) |
0.0% (0/21) |
0.79 | 0.0% (0/18) |
ACE = angiotensin converting enzyme, LV = left ventricular, LVEDD = left ventricular enddiastolic diameter
* as defined for Euroscore II